Roy Decker MD/PhD

Associate Professor of Therapeutic Radiology and Assistant Professor of Surgery (Otolaryngology); Clinical Research Program Leader, Therapeutic Radiology, Yale Cancer Center

Specialties & Subspecialties

Cancer Center, Yale: Head and Neck Cancer Surgery Program | Thoracic Oncology Program

Therapeutic Radiology/Radiation Oncology

Surgery

Radiation Oncology

Education & Training

  • B.A., University of Virginia (1988)
  • M.D./Ph.D., Medical College of Virginia, Richmond, Virginia (2002)
  • Resident, Yale-New Haven Hospital , Radiation Oncology (2003 - 2007)
  • Intern, Medical College of Virginia Hospital , Internal Medicine

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Head & Neck Cancer; Lung Cancer; Stereotactic Body Radiosurgery


Cancers Treated

Brachytherapy, Head & Neck, Lung, Prostate, Stereotactic Radiosurgery


Board Certifications

  • Therapeutic Radiology, Board Certified (2008)

Clinical Trials

ConditionsStudy Title
Head and Neck Cancer, Larynx, and Lip, Oral Cavity and PharynxRTOG 0920: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer {CIRB}
RTOG 1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck {CIRB}
Brain and Nervous System and Other Respiratory and Intrathoracic OrgansA randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma
LungLCCC 1123: Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR Tyrosine Kinase Inhibitor (TKI)
RectumKD018: Pilot Trial of KD018 with Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients with Locally Advanced Rectal Cancer

Edit Profile